FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316063260> ?p ?o ?g. }

• W2316063260 endingPage "24526" @default.
• W2316063260 startingPage "24510" @default.
• W2316063260 abstract "// Qing-yong Chen 1, * , De-min Jiao 1, * , Jian Wang 1, * , Huizhen Hu 1, * , Xiali Tang 1 , Jun Chen 1 , Hao Mou 1 , Wei Lu 2 1 Department of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, 310013, P.R. China 2 Department of Oncology, The 117th Hospital of PLA, Hangzhou, Zhejiang, 310013, P.R. China * These authors have contributed equally to this work Correspondence to: Qingyong Chen, e-mail: cqyong117@163.com Wei Lu, e-mail: luwei3603@163.com Keywords: miR-206, cisplatin resistance, epithelial-mesenchymal transition (EMT), MET, lung adenocarcinoma Received: April 27, 2015      Accepted: March 04, 2016      Published: March 21, 2016 ABSTRACT MicroRNAs (miRNAs) play a critical role in drug resistance and epithelial-mesenchymal transition (EMT). The aims of this study were to explore the potential role of miR-206 in governing cisplatin resistance and EMT in lung cancer cells. We found that both lung adenocarcinoma A549 cisplatin-resistant cells (A549/DDP) and H1299 cisplatin-resistant cells (H1299/DDP) acquired mesenchymal features and were along with low expression of miR-206 and high migration and invasion abilities. Ectopic expression of miR-206 mimics inhibited cisplatin resistance, reversed the EMT phenotype, decreased the migration and invasion in these DDP-resistant cells. In contrast, miR-206 inhibitors increased cisplatin resistance, EMT, cell migration and invasion in non-DDP-resistant cells. Furthermore, we found that MET is the direct target of miR-206 in lung cancer cells. Knockdown of MET exhibited an EMT and DDP resistant inhibitory effect on DDP-resistant cells. Conversely, overexpression of MET in non-DDP- resistant cells produced a promoting effect on cell EMT and DDP resistance. In lung adenocarcinoma tissues, we demonstrated that low expression of miR-206 were also correlated with increased cisplatin resistance and MET expression. In addition, we revealed that miR-206 overexpression reduced cisplatin resistance and EMT in DDP-resistant cells, partly due to inactivation of MET/PI3K/AKT/mTOR signaling pathway, and subsequent downregulation of MDR1, ZEB1 and Snail expression. Finally, we found that miR-206 could also sensitize A549/DDP cells to cisplatin in mice model. Taken together, our study implied that activation of miR-206 or inactivation of its target gene pathway could serve as a novel approach to reverse cisplatin resistance in lung adenocarcinomas cells." @default.
• W2316063260 created "2016-06-24" @default.
• W2316063260 creator A5004372852 @default.
• W2316063260 creator A5005754381 @default.
• W2316063260 creator A5017651819 @default.
• W2316063260 creator A5032764121 @default.
• W2316063260 creator A5040693527 @default.
• W2316063260 creator A5079367518 @default.
• W2316063260 creator A5082857859 @default.
• W2316063260 creator A5087750293 @default.
• W2316063260 date "2016-03-21" @default.
• W2316063260 modified "2023-10-02" @default.
• W2316063260 title "miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET" @default.
• W2316063260 cites W1126019608 @default.
• W2316063260 cites W1483316103 @default.
• W2316063260 cites W1509711666 @default.
• W2316063260 cites W1523816934 @default.
• W2316063260 cites W1591399906 @default.
• W2316063260 cites W1604468403 @default.
• W2316063260 cites W1828795946 @default.
• W2316063260 cites W1901242447 @default.
• W2316063260 cites W1976785311 @default.
• W2316063260 cites W1987281549 @default.
• W2316063260 cites W1992845343 @default.
• W2316063260 cites W1996503855 @default.
• W2316063260 cites W2005403381 @default.
• W2316063260 cites W2047889405 @default.
• W2316063260 cites W2052456024 @default.
• W2316063260 cites W2055904567 @default.
• W2316063260 cites W2059868013 @default.
• W2316063260 cites W2071110157 @default.
• W2316063260 cites W2074191719 @default.
• W2316063260 cites W2076002185 @default.
• W2316063260 cites W2077419075 @default.
• W2316063260 cites W2079484912 @default.
• W2316063260 cites W2089858439 @default.
• W2316063260 cites W2091729045 @default.
• W2316063260 cites W2093163206 @default.
• W2316063260 cites W2097567676 @default.
• W2316063260 cites W2097760889 @default.
• W2316063260 cites W2107312379 @default.
• W2316063260 cites W2110146698 @default.
• W2316063260 cites W2113565145 @default.
• W2316063260 cites W2121291985 @default.
• W2316063260 cites W2132930491 @default.
• W2316063260 cites W2137807084 @default.
• W2316063260 cites W2145637287 @default.
• W2316063260 cites W2150322923 @default.
• W2316063260 cites W2150670229 @default.
• W2316063260 cites W2153906296 @default.
• W2316063260 cites W2157755159 @default.
• W2316063260 cites W2157923000 @default.
• W2316063260 cites W2162198780 @default.
• W2316063260 cites W2163134976 @default.
• W2316063260 cites W2167246201 @default.
• W2316063260 cites W2168767893 @default.
• W2316063260 cites W903460745 @default.
• W2316063260 doi "https://doi.org/10.18632/oncotarget.8229" @default.
• W2316063260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5029718" @default.
• W2316063260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27014910" @default.
• W2316063260 hasPublicationYear "2016" @default.
• W2316063260 type Work @default.
• W2316063260 sameAs 2316063260 @default.
• W2316063260 citedByCount "78" @default.
• W2316063260 countsByYear W23160632602016 @default.
• W2316063260 countsByYear W23160632602017 @default.
• W2316063260 countsByYear W23160632602018 @default.
• W2316063260 countsByYear W23160632602019 @default.
• W2316063260 countsByYear W23160632602020 @default.
• W2316063260 countsByYear W23160632602021 @default.
• W2316063260 countsByYear W23160632602022 @default.
• W2316063260 countsByYear W23160632602023 @default.
• W2316063260 crossrefType "journal-article" @default.
• W2316063260 hasAuthorship W2316063260A5004372852 @default.
• W2316063260 hasAuthorship W2316063260A5005754381 @default.
• W2316063260 hasAuthorship W2316063260A5017651819 @default.
• W2316063260 hasAuthorship W2316063260A5032764121 @default.
• W2316063260 hasAuthorship W2316063260A5040693527 @default.
• W2316063260 hasAuthorship W2316063260A5079367518 @default.
• W2316063260 hasAuthorship W2316063260A5082857859 @default.
• W2316063260 hasAuthorship W2316063260A5087750293 @default.
• W2316063260 hasBestOaLocation W23160632601 @default.
• W2316063260 hasConcept C104317684 @default.
• W2316063260 hasConcept C114851261 @default.
• W2316063260 hasConcept C121608353 @default.
• W2316063260 hasConcept C126322002 @default.
• W2316063260 hasConcept C143998085 @default.
• W2316063260 hasConcept C145059251 @default.
• W2316063260 hasConcept C173396325 @default.
• W2316063260 hasConcept C190283241 @default.
• W2316063260 hasConcept C2776256026 @default.
• W2316063260 hasConcept C2776694085 @default.
• W2316063260 hasConcept C2778239845 @default.
• W2316063260 hasConcept C2779013556 @default.
• W2316063260 hasConcept C2781182431 @default.
• W2316063260 hasConcept C502942594 @default.
• W2316063260 hasConcept C54355233 @default.
• W2316063260 hasConcept C71924100 @default.

• next